What is ResMed's expected EPS for Q4 2026?

Analysts expect ResMed (RMD) to report consensus EPS of approximately $2.89 for Q4 2026. Estimates range from $2.78 to $2.98.

What revenue do analysts expect for ResMed in Q4 2026?

The consensus revenue forecast for ResMed (RMD) in Q4 2026 is approximately $1.46B. Forecasts range from $1.43B to $1.5B.

How many analysts cover ResMed?

6 analysts contribute to the ResMed (RMD) Q4 2026 consensus estimate.

Has ResMed beaten earnings estimates recently?

ResMed beat analyst EPS estimates in 1 of the last 1 quarter. ResMed beat revenue estimates in 1 of 1. In the most recent quarter (Q3 2026), ResMed EPS beat by 2.3% and revenue beat by 0.8%.

When does ResMed report Q4 2026 earnings?

ResMed (RMD) is expected to report Q4 2026 earnings on August 6, 2026 after market close.

RMD Q4 2026 earnings estimate

Consensus EPS · Q4 2026

$2.89

Consensus revenue · Q4 2026

$1.5B

Analysts

Expected report

Aug 6, 2026

After close

Upcoming earnings

Locks in 14 days 9 hours · AMC: Locks at 4:00 PM ET on report day

Revenue$1.5B$1.4B – $1.5B

EPS$2.89$2.78 – $2.98

What to watch

Analyst ratings: Downgrades trending

Make your prediction

Analyst consensus

Based on estimates from 6 analysts.

Metric	Low	Consensus	High
Revenue	$1.4B	$1.5B	$1.5B
EPS	$2.78	$2.89	$2.98
EBITDA	$576.6M	$580.6M	$584.6M
EBIT	$533.8M	$537.5M	$541.2M
Net income	$421.1M	$426.9M	$434.3M

Revenue$1.5B
EPS$2.89
EBITDA$580.6M
EBIT$537.5M
Net income$426.9M

Historical beat/miss

Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.

Period	Rev. actual	Rev. est.	Rev. surprise	EPS actual	EPS est.	EPS surprise
Q3 2026	$1.4B	$1.4B	+0.8%	$2.86	$2.80	+2.3%

Q3 2026+0.8%+2.3%

Estimate revisions

How analyst consensus estimates have changed over the past 90 days.

Collecting data

Revision trends appear once we have collected at least two daily snapshots for this period.

Community vs analysts

See how the TickerLeague crowd's forecast stacks up against Wall Street.

Be the first to predict

No community consensus for ResMed (RMD) Q4 2026 yet. Make a prediction to start the crowd forecast.

Make your prediction

Analyst price target

Based on price targets from 6 analysts.

Low: $220.00
Consensus: $247.27
Median: $234.00
High: $300.00
Current: $192.91
Upside: +28.2%

Upside calculated vs most recent trading price of $192.91.

Analyst ratings

Consensus: Hold — based on 35 analyst ratings.

Buy 14Hold 16Sell 5

24-month trend

Recent analyst actions

Date	Firm	Action	From	To
Jul 15, 2026	Mizuho	maintain	Outperform	Outperform
Jul 13, 2026	Citigroup	downgrade	Buy	Neutral
Jul 10, 2026	Jefferies	maintain	Hold	Hold
Jul 8, 2026	Wells Fargo	maintain	Equal Weight	Equal Weight
Jul 8, 2026	RBC Capital	maintain	Outperform	Outperform
Jun 22, 2026	Keybanc	maintain	Overweight	Overweight
Jun 17, 2026	Morgan Stanley	downgrade	Overweight	Equal Weight
Jun 15, 2026	Citigroup	maintain	Buy	Buy
May 1, 2026	Wells Fargo	maintain	Equal Weight	Equal Weight
May 1, 2026	RBC Capital	maintain	Outperform	Outperform

Jul 15, 2026MizuhoOutperform
Jul 13, 2026CitigroupNeutral
Jul 10, 2026JefferiesHold
Jul 8, 2026Wells FargoEqual Weight
Jul 8, 2026RBC CapitalOutperform
Jun 22, 2026KeybancOverweight
Jun 17, 2026Morgan StanleyEqual Weight
Jun 15, 2026CitigroupBuy
May 1, 2026Wells FargoEqual Weight
May 1, 2026RBC CapitalOutperform

Frequently asked questions

ResMed (RMD) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

RMD Overview

Counters

Income Statement

Cash Flow

Capital Return

How this company returns cash to shareholders — buybacks, dividends, and stock splits.

Forecast & Valuation